In the third model, where sc 5 × 106 HCC1954 xenografts were treated with iv PBMC (5 × 106, q wk × 3 weeks), and iv HER2-BsAb (100 ug, 2 ×/wk × 3 weeks), tumor growth was substantially delayed (two separate experiments), in contrast to only modest effects for PBMC + trastuzumab + huOKT3, PBMC + trastuzumab, or PBMC + huOKT3 (Fig. 4D). The gene discussed is ERBB2; the disease is neoplasm.